High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L). // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2666364326001050?dgcid=rss_sd_all
High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L). JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S2666364326001050?dgcid=rss_sd_all
“High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L).” JTO Clinical and Research Reports.
@article{article56908,
title = {High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2666364326001050?dgcid=rss_sd_all}
}